By Rev. Alvin C. Hathaway Sr.
For more than three decades, my work has been rooted in West Baltimore, where the gap between scientific progress and community benefit is not theoretical; it is something families experience every day.
That is why a recent announcement about a new treatment for metastatic pancreatic cancer demanded my attention. New clinical data shows that daraxonrasib doubled survival rates for patients with previously treated metastatic pancreatic cancer, reducing the risk of death by
Our editorial team includes several staff writers, each contributing their specialized knowledge to enhance the depth and breadth of our event and story coverage.